0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > OX40

OX40

OX40 Molecule Information

Name:Tumor necrosis factor receptor superfamily member 4
Target Synonym:ATC35 Antigen?OX40 Antigen?ACT35?IMD16?OX40?Receptors? OX40?ACT35 antigen?TNFRSF4?CD134?TNF Receptor Superfamily Member 4?TAX Transcriptionally-Activated Glycoprotein 1 Receptor?CD134 Antigen?TXGP1L?Tumor Necrosis Factor Receptor Superfamily? Member 4?Lym
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Phase 2 Clinical

OX40 Protein Product ListCompare or Buy

OX40 Part of Bioactivity data

OX0-H5252-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.01 μg/mL (Routinely tested).

OX0-H82F7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Biotinylated Human OX40, Fc,Avitag (Cat. No. OX0-H82F7) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.1 μg/mL (Routinely tested).

TN4-H82E4-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TN4-H82E4-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

OX40 Molecule Synonym Name

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

OX40 Molecule Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

OX40 References

OX40 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Shattuck Labs Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
PF-04518600 PF-8600; PF-04518600 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Carcinoma, Renal Cell; Neoplasms; Lymphoma, Follicular; Breast Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell Details
INBRX-106 INBRX-106 Phase 1 Clinical Inhibrx Head and Neck Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
BGB-A445 BGB-A445 Phase 1 Clinical Beigene Ltd Neoplasms Details
Recombinant human anti-OX40 monoclonal antibody (Innovent Biologics) IBI-101 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
MEDI-6469 MEDI-6469 Phase 2 Clinical Providence Cancer Center, Agonox Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma Details
Vonlerolizumab RG-7888; MOXR-0916; RO-7021608 Phase 1 Clinical Genentech Inc Carcinoma, Transitional Cell; Neoplasms Details
Tavolimab MEDI-0562 Phase 1 Clinical Medimmune Ovarian Neoplasms; Neoplasms Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) Phase 1 Clinical Livzon Pharmaceutical Group Neoplasms Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
KHK-4083 KHK-4083 Phase 2 Clinical Kyowa Hakko Kirin Co Ltd Abdominal Pain; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases Details
GSK3174998 GSK3174998; GSK 3174998; GSK-3174998 Phase 2 Clinical Glaxosmithkline Plc Head and Neck Neoplasms; Neoplasms; Multiple Myeloma Details
BMS-986178 BMS-986178 Phase 2 Clinical Bristol-Myers Squibb Company Neoplasms Details
ATOR-1015 ADC-1015; ATOR-1015 Phase 1 Clinical Alligator Bioscience Neoplasms Details
INCAGN-1949 INCAGN-1949 Phase 2 Clinical Agenus Inc, Ludwig Institute For Cancer Research Carcinoma, Renal Cell; Urogenital Neoplasms; Neoplasm Metastasis Details
GBR-830 GBR-830 Phase 2 Clinical Glenmark Pharmaceuticals Ltd Dermatitis, Atopic Details
Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) YH-002 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours Details
mRNA-2416 mRNA-2416; OX40L mRNA - Moderna Therpeutics Phase 2 Clinical Moderna Therapeutics Ovarian Neoplasms; Lymphoma Details

This web search service is supported by Google Inc.

totop